Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial

Trials

Volumn 13, Issue , 2012, Pages

  Seinstra, Beatrijs A ^a   Defreyne, Luc ^b   Lambert, Bieke ^b   Lam, Marnix G E H ^a   Verkooijen, Helena M ^a   van Erpecum, Karel J ^a   van Hoek, Bart ^c   van Erkel, Arian R ^c   Coenraad, Minneke J ^c   Al Younis, Imad ^c   van Vlierberghe, Hans ^b   van den Bosch, Maurice A A J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MICROSPHERE; YTTRIUM 90;

ADULT; ANGIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; HEALTH CARE COSTS; HEPATIC ARTERY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICROSPHERES; NETHERLANDS; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84865229452     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-144     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34. 10.1053/j.gastro.2004.09.013, 15508094.
3. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007, 25:978-986. 10.1200/JCO.2006.09.8657, 17350947.
4. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004, 10:S115-S120. 10.1002/lt.20034, 14762851.
5. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616. 10.1016/S0140-6736(09)60381-0, 19231618.
6. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969-977. 1942491, 13197542.
7. Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol 2007, 10:2-11. 10.1053/j.tvir.2007.08.008, 17980314.
8. Buijs M, Vossen JA, Frangakis C, Hong K, Georgiades CS, Chen Y, Liapi E, Geschwind JF. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization-single-center experience. Radiology 2008, 249:346-354. 10.1148/radiol.2483071902, 18796686.
9. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009, 9:1920-1928. 10.1111/j.1600-6143.2009.02695.x, 19552767.
10. Lewandowski RJ, Mulcahy MF, Kulik LM, Riaz A, Ryu RK, Baker TB, Ibrahim SM, Abecassis MI, Miller FH, Sato KT, Senthilnathan S, Resnick SA, Wang E, Gupta R, Chen R, Newman SB, Chrisman HB, Nemcek AA, Vogelzang RL, Omary RA, Benson AB, Salem R. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010, 255:955-965. 10.1148/radiol.10091473, 2948657, 20501733.
11. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739. 10.1016/S0140-6736(02)08649-X, 12049862.
12. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171. 10.1053/jhep.2002.33156, 11981766.
13. Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54. 10.1148/radiol.2241011262, 12091661.
14. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
15. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011, 3:1-60.
16. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, Bargellini I, Petruzzi P, Massa SC, Crespi S, Sarti I. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008, 31:1141-1149. 10.1007/s00270-008-9409-2, 18696150.
17. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, Delis S, Gouliamos A, Kelekis D. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008, 31:269-280. 10.1007/s00270-007-9226-z, 17999110.
18. Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, Gallardo E, Kelekis A, Gouliamos A, Kelekis D. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008, 33:512-519. 10.1007/s00261-007-9334-x, 17938995.
19. Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007, 5:1100-1108. 10.1016/j.cgh.2007.04.021, 17627902.
20. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montana X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481. 10.1016/j.jhep.2006.10.020, 17239480.
21. Wigmore SJ, Redhead DN, Thomson BN, Currie EJ, Parks RW, Madhavan KK, Garden OJ. Postchemoembolisation syndrome-tumour necrosis or hepatocyte injury?. Br J Cancer 2003, 89:1423-1427. 10.1038/sj.bjc.6601329, 2394347, 14562011.
22. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33:41-52. 10.1007/s00270-009-9711-7, 2816794, 19908093.
23. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011, 34:422-431. 10.1097/COC.0b013e3181df0a50, 20622645.
24. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, van Het Schip AD, Nijsen JF. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009, 19:951-959. 10.1007/s00330-008-1211-7, 18989675.
25. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64. 10.1053/j.gastro.2009.09.006, 19766639.
26. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA, Kim HS. Comparison of Yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010, 21:224-230. 10.1016/j.jvir.2009.10.013, 20022765.
27. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010, 116:1305-1314. 10.1002/cncr.24884, 2829376, 20066715.
28. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011, 140:497-507. 10.1053/j.gastro.2010.10.049, 3129335, 21044630.
29. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010, 53:1020-1022.
30. Altman DG, Bland JM. Treatment allocation by minimisation. BMJ 2005, 330:843. 10.1136/bmj.330.7495.843, 556084, 15817555.
31. Barentsz MW, Vente MA, Lam MG, Smits ML, Nijsen JF, Seinstra BA, Rosenbaum CE, Verkooijen HM, Zonnenberg BA, Van den Bosch MA. Technical solutions to ensure safe yttrium-90 radioembolization in patients with initial extrahepatic deposition of (99 m)technetium-albumin macroaggregates. Cardiovasc Intervent Radiol 2011, 34:1074-1079. 10.1007/s00270-010-0088-4, 3170462, 21191588.
32. Lambert B, Mertens J, Sturm EJ, Stienaers S, Defreyne L, D'Asseler Y. 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging 2010, 37:2328-2333. 10.1007/s00259-010-1566-2, 20683591.
33. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60. 10.1055/s-0030-1247132, 20175033.